Our featured story this week! Role of Glutamine Synthetase in Angiogenesis beyond Glutamine Synthesis TEST waguri Harvard Medical School nature CarmelietLab ow.ly/Ys0z30lMbCc

Today is #WorldCancerDay 🍀. At the CCB we focus every day on #Cancer research, raise #Awareness about it and make it a global priority to #improve early #diagnosis & #discover effective #treatments for all patients.

Oncurious NV Receives $1 M Grant from VLAIO to Progress Pipeline of Next Generation Cancer Immunotherapies bit.ly/2XFrRZ4 #nextlevel

Congrats to the @Oxurion and Bicycle Therapeutics team ! 👏

Moreover, bij Oncurious zijn we #ontrack om rond mid 2020 een eerste preklinische PoC voor te stellen We werken aan immuno-oncotherapieën van de volgende generatie voor een breed spectrum van kankertypes. @Oxurion is 85% eigenaar, VIB 15% #partnersinscience

We've got news from our I-O portfolio! Oncurious VIB Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program. Follow the link to our updated website: bit.ly/31OLHoX

Journal of ImmunoTherapy for Cancer published research findings by Oncurious VIB highlighting efficacy and safety of targeting CCR8 for depletion of tumor-promoting ti-Tregs in combo with anti-PD-1 therapy ap.lc/k3RWw #immunotherapy #cancer #CCR8 #leuven

Excited to attend and present preclinical and clinical data at the AACR 2021 Annual Meeting! thttps://bit.ly/2PGc2md #ccr8 #immunotherapy #tb403 #medulloblastoma

Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in Paediatric Subjects with Relapsed or Refractory Medulloblastoma Presented at the American Association for Cancer Research 2021 Annual Meeting globenewswire.com/news-release/2…

Very excited and proud to present encouraging data from a Phase 1 Phase 1 Dose Escalation Study of #TB403 in Paediatric Subjects with Relapsed or Refractory Medulloblastoma bit.ly/3uHNRlZ #AACR21 #cancerresearch Oncurious BeatChildhoodCancer VIB CarmelietLab

Beursblik: bemoedigende resultaten bij Oncurious 💪shar.es/aoQQj1

As we close out #BrainTumorAwarenessMonth, we hope you will join us & #GiveHopeAName by making a donation to Pediatric Brain Tumor Foundation in honor of every child who has battled a brain tumor. Donate today: buff.ly/2ToF7UG #CareCureThrive #BrainCancerAwareness #GoGray #BrainTumorAwareness

Published papers by @Oxurion in the Journal of Pharmacokinetics and Pharmacodynamics describe desirable #clinicalstudy profiles of THR-149 and THR-687 for #retinalvascular disorders: oxurion.com/content/oxurio… #lifesciences #biopharma #publishing #opthamology

Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal globenewswire.com/news-release/2…

. @Oxurion publishes results from Phase 1 trial of THR-687 for #DME treatment; is now recruiting patients for Phase 2 clinical study buff.ly/3AMjs9c

Oncurious to buy VIB’s Immune-Oncology portfolio ow.ly/pBey30eVEjA

Congratulations to the @ThromboGenics and @NovartisPharma team! x.com/ThromboGenics/…

Hij vertrok vanuit #Leuven om elke dag 76 kilometer te lopen. Aangekomen! Van harte gefeliciteerd Johan Swinnen ! goo.gl/7FLMZ1

Congratulations to Prof Peter Carmeliet CCB_VIB_KUL VIB ! Well deserved! x.com/VIBLifeScience…

Congratulations @ThromboGenics ! x.com/ThromboGenics/…